共 50 条
Comorbidities in spondyloarthritis including psoriatic arthritis
被引:28
|作者:
Molto, Anna
[1
,2
,3
]
Dougados, Maxime
[1
,2
,3
]
机构:
[1] Paris Descartes Univ, Hop Cochin, AP HP, Dept Rheumatol, Paris, France
[2] PRES Sorbonne Paris Cite, INSERM U1153, Clin Epidemiol & Biostat, Paris, France
[3] Hop Cochin, Serv Rhumatol B, 27 Rue Fg St Jacques, F-75014 Paris, France
来源:
关键词:
Spondyloarthritis;
Comorbidities;
Systematic review;
BONE-MINERAL DENSITY;
INFLAMMATORY-BOWEL-DISEASE;
ANKYLOSING-SPONDYLITIS;
RHEUMATOID-ARTHRITIS;
VERTEBRAL FRACTURES;
SERIOUS INFECTIONS;
MALIGNANT-LYMPHOMA;
COLORECTAL-CANCER;
INHIBITOR THERAPY;
CLINICAL-TRIALS;
D O I:
10.1016/j.berh.2018.09.002
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Comorbidities in spondyloarthritis (SpA) including psoriatic arthritis have to be differentiated to the concept of clinical features of SpA (e.g., uveitis, psoriasis, and inflammatory bowel disease). In addition to atherosclerosis-related cardiovascular diseases, the most frequent comorbidities in SpA are osteoporosis, fibromyalgia, and depression. Moreover, the current available drug therapies (e.g., NSAIDs, corticosteroids, and biologics) might increase the risk of some comorbidities such as infections and gastrointestinal disorders. Awareness about these comorbidities is crucial to improve their screening and management. For this purpose, any systematic periodical review should integrate a program (ideally internationally standardized) focused on comorbidities. (C) 2018 Published by Elsevier Ltd.
引用
收藏
页码:390 / 400
页数:11
相关论文